|
Variable, change from baseline
|
LM25 (N = 80)
|
IGL (N = 82)
|
|---|
|
Baseline
|
Change from baseline
|
Baseline
|
Change from baseline
|
|---|
|
ITSQ, mean (SD)
|
|
Inconvenience of regimen
|
92.7 (10.7)
|
−1.5 (11.0)
|
92.2 (12.1)
|
0.5 (11.2)
|
|
Lifestyle flexibility
|
82.9 (21.2)
|
−0.1 (24.1)
|
84.7 (17.6)
|
−4.8 (24.9)
|
|
Glycemic control
|
80.9 (19.9)
|
6.9 (20.0)
|
78.3 (21.7)
|
10.3 (22.1)
|
|
Hypoglycemic control
|
85.5 (14.7)
|
−2.7 (17.7)
|
85.7 (17.8)
|
0.1 (17.0)
|
|
Insulin delivery device satisfaction
|
86.9 (15.7)
|
4.2 (16.1)
|
88.6 (14.3)
|
1.1 (10.6)
|
|
Total score
|
86.5 (11.4)
|
1.1 (11.6)
|
86.8 (12.4)
|
1.2 (10.6)
|
|
PAM-D21, mean (SD)
|
|
Convenience/flexibility
|
90.0 (16.0)
|
−0.7 (21.2)
|
91.7 (13.8)
|
−1.2 (16.8)
|
|
Perceived effectiveness
|
74.6 (20.7)
|
5.9 (23.7)
|
72.0 (20.5)
|
12.0 (25.4)
|
|
Emotional effects
|
84.2 (20.2)
|
1.0 (21.7)
|
86.8 (17.5)
|
−0.2 (22.4)
|
|
Physical effects
|
87.0 (13.4)
|
1.0 (12.8)
|
90.5 (12.9)
|
1.1 (10.4)
|
-
IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, ITSQ insulin treatment satisfaction questionnaire, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, PAM-D21 perceptions about medications-diabetes 21, SD standard deviation
